|14.50||-0.4100||-2.75%||Vol 261.94K||1Y Perf -4.34%|
|Sep 24th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||29.00||Analyst Rating||Strong Buy 1.00|
|Potential %||100.00||Finscreener Ranking||★★★★★ 61.24|
|Insiders Trans % 3/6/12 mo.||-/-/-11||Value Ranking||★★★ 50.58|
|Insiders Value % 3/6/12 mo.||-/-/-33||Growth Ranking||★★★★+ 62.70|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-31||Income Ranking||— -|
|Price Range Ratio 52W %||63.98||Earnings Rating||Neutral|
|Market Cap||456.87M||Earnings Date||16th Nov 2021|
Today's Price Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||16th Nov 2021|
|Estimated EPS Next Report||-0.39|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||397.25K|
|Avg. Monthly Volume||292.71K|
|Avg. Quarterly Volume||227.36K|
Cue Biopharma Inc. (NASDAQ: CUE) stock closed at 14.5 per share at the end of the most recent trading day (a -2.75% change compared to the prior day closing price) with a volume of 262.04K shares and market capitalization of 456.87M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 47 people. Cue Biopharma Inc. CEO is Daniel R. Passeri.
The one-year performance of Cue Biopharma Inc. stock is -4.34%, while year-to-date (YTD) performance is 15.91%. CUE stock has a five-year performance of %. Its 52-week range is between 9.65 and 17.23, which gives CUE stock a 52-week price range ratio of 63.98%
Cue Biopharma Inc. currently has a PE ratio of -9.00, a price-to-book (PB) ratio of 5.58, a price-to-sale (PS) ratio of 76.19, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -45.98%, a ROC of -53.05% and a ROE of -57.39%. The company’s profit margin is -%, its EBITDA margin is -781.90%, and its revenue ttm is $5.47 Million , which makes it $0.17 revenue per share.
Of the last four earnings reports from Cue Biopharma Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.39 for the next earnings report. Cue Biopharma Inc.’s next earnings report date is 16th Nov 2021.
The consensus rating of Wall Street analysts for Cue Biopharma Inc. is Strong Buy (1), with a target price of $29, which is +100.00% compared to the current price. The earnings rating for Cue Biopharma Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cue Biopharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cue Biopharma Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 15.28, ATR14 : 0.95, CCI20 : 174.51, Chaikin Money Flow : 0.09, MACD : 0.79, Money Flow Index : 76.68, ROC : 25.76, RSI : 68.98, STOCH (14,3) : 74.49, STOCH RSI : 0.65, UO : 57.27, Williams %R : -25.51), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cue Biopharma Inc. in the last 12-months were: Aaron Fletcher (Buy at a value of $82 776), Anish Suri (Option Excercise at a value of $0), Cameron Gray (Buy at a value of $151 500), Kenneth J. Pienta (Buy at a value of $40 980), Kenneth J. Pienta (Option Excercise at a value of $139 365), Kenneth J. Pienta (Sold 36 433 shares of value $550 641 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.